The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Nonurgent appointments should be postponed; use of telemedicine encouraged when feasible.
Pfizer announced the launch of 3 new biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab-qyyp). Zirabev, a biosimilar to Avastin (bevacizumab; Genentech), is available for the treatment of 5 types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent…
The Food and Drug Administration (FDA) has granted Orphan Drug Designation to zotiraciclib (Adastra Pharmaceuticals) for the treatment of glioma.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
Statin use tied to reduction in stroke incidence for cardiac patients with thorax and head or neck cancer
The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.
Two separate oral rinses were found to reduce pain from oral mucositis and mouth sores in patients receiving radiation therapy for head and neck cancers when compared to placebo.
Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online in Nature Medicine.
For patients with recurrent or metastatic head and neck squamous cell carcinoma, pembrolizumab has a favorable safety profile and is associated with prolongation of overall survival.
